Skye Bioscience, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system. With a focus on obesity and ocular indications, Skye is dedicated to unlocking the pharmaceutical potential of the endocannabinoid system to treat diseases with metabolic, inflammatory, and fibrotic processes.